Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02837328 · ClinicalTrials.gov registry record · Phase 2
Magnesium Supplementation for the Prevention of Supraventricular Arrhythmias
A Phase 2 study of Premature Atrial Contraction, sponsored by University of Minnesota.
- Completed
- Registry status
- Phase 2
- Development phase
- 59
- Enrollment target
- 1
- Study location
NCT02837328: Completed Phase 2 study of Premature Atrial Contraction, sponsored by University of Minnesota.
NCT02837328 is a Phase 2 study of Premature Atrial Contraction that has completed, run by University of Minnesota. The registered enrollment target is 59 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (56% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02837328, a Phase 2 study of Premature Atrial Contraction, has completed, sponsored by University of Minnesota.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 59 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary objective of this research is to determine whether oral magnesium supplementation in healthy, community-living individuals will be associated with reductions in the burden of arrhythmias in the upper chambers of the heart (supraventricular arrhythmias).
Primary Outcome
The primary endpoint will be the change in burden of PACs
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Oral Magnesium Supplement
Study Locations (1)
Minnesota
- University of Minnesota - Twin Cities - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 59 participants |
| Start Date | 2017-03-01 |
| Est. Completion | 2017-09-15 |
| Phase | Phase 2 |
What the finished NCT02837328 record still lists
NCT02837328 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 59 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (56% lower).
The record links to 1 condition, with Premature Atrial Contraction appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02837328 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT02837328 about?
NCT02837328 is a clinical study titled "Magnesium Supplementation for the Prevention of Supraventricular Arrhythmias". The primary objective of this research is to determine whether oral magnesium supplementation in healthy, community-living individuals will be associated with reductions in the burden of arrhythmias in the upper chambers of the heart (supraventricular arrhythmias).
What is the current status of trial NCT02837328?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 59 participants. The study started on 2017-03-01. Estimated completion is 2017-09-15.
What conditions does trial NCT02837328 study?
This clinical trial studies the following conditions: Premature Atrial Contraction.
What interventions are being tested in trial NCT02837328?
The interventions under investigation include: Placebo (DRUG), Oral Magnesium Supplement (DRUG).
Who is sponsoring clinical trial NCT02837328?
This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02837328 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Premature Atrial Contraction
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02837328's enrollment target sits among peer trials
59 1133rd of 2000 higher than 866 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03801083 · 59 participants · Phase 2
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Biliary Tract Cancers
- NCT04332367 · 59 participants · Phase 2
Carboplatin, Taxane And Ramucirumab for Patients With NSCLC After Pemetrexed or Pembrolizumab Maintenance
- NCT05489575 · 59 participants · NA
CPAP for the Treatment of Supine Hypertension
- NCT06721689 · 59 participants · Phase 1
PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI